Omega has conditionally raised £8m alongside an Open Offer up to £3m, to scale manufacturing, expand its lateral flow portfolio of global health tests and exploit the opportunities for COVID-19 testing that arise from its partnerships within the UK. We argue that the Food Intolerance business largely underpins the current valuation, given imminent Chinese approval, with upside derived from VISITECT and COVID-19 opportunities. Modelling the potential impact of a COVID-19 test with
22 Jun 2020
Omega Diagnostics - £8m fundraise with Open Offer of up to £3m
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - £8m fundraise with Open Offer of up to £3m
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.2 0 0.0% | Mkt Cap: 7.73m
- Published:
22 Jun 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
16
Omega has conditionally raised £8m alongside an Open Offer up to £3m, to scale manufacturing, expand its lateral flow portfolio of global health tests and exploit the opportunities for COVID-19 testing that arise from its partnerships within the UK. We argue that the Food Intolerance business largely underpins the current valuation, given imminent Chinese approval, with upside derived from VISITECT and COVID-19 opportunities. Modelling the potential impact of a COVID-19 test with